Top 5 Most-Read Immuno-Oncology Articles of 2023

Our top 5 most-read immuno-oncology articles of 2023 included coverage of new guidelines, novel therapy approaches, and the progress and challenges that have been seen in the immuno-oncology landscape.

Check out our immuno-oncology page for more content.

5. Early Recognition Key to Management of Immunotherapy Toxicities

A session at the 2023 National Comprehensive Cancer Network Annual Conference discussed guideline updates in the management of immune-related adverse events—a key aspect to making immunotherapies available in community settings. Presenters gave an overview of phases of the immune cycle, examples of cases in which toxicities were addressed, and the treatment of oral toxicities, which is an increasingly recognized area in the guidelines.

Read the full article here.

4. With Broad Input, Clinical Pathways Making a Difference for End Users

A panel discussion at the 11th annual Patient-Centered Oncology Care^® conference in Nashville, Tennessee, covered the topic “Why Clinical Pathway Adoption Is a Team Sport.” Participants gave overviews of their roles within pathways and provided insight into the nuances of making clinical pathways effective, such as teamwork, incorporation of patient feedback, and how to encourage providers to utilize pathways.

Read the full article here.

3. Long-Term Data Show Consistent OS Benefit With Nivolumab Plus Ipilimumab in mNSCLC

Updated results from part 1 of the phase 3 CheckMate-227 trial demonstrate consistent, long-term benefits with first-line nivolumab plus ipilimumab compared with chemotherapy in metastatic non–small cell lung cancer (NSCLC). In the primary end point population of patients with stage IV or recurrent, treatment-naïve NSCLC PD-L1 expression of 1% or higher with no known EGFR or ALK genomic tumor mutations, 6-year survival was 22% with immunotherapy vs 13% with chemotherapy. The findings, presented at the 2023 World Conference on Lung Cancer, speak to the combination's potential to improve outcomes for certain patients with NSCLC.

Read the full article here.

2. Review Highlights Progress, Challenges With CRS in Cancer Immunotherapies

A review published in Frontiers in Immunology highlighted both the substantial progress made with the advent of immunotherapy and the challenges associated with toxicities—namely, cytokine release syndrome (CRS). Researchers discussed the history of CRS, which first appeared in scientific literature in the early 1990s, as well as the state of its management decades later. They also dug into the currently available research on CRS in the context of cancer immunotherapy, including how commonly it occurs across different therapy types.

Read the full article here.

1. Moderna and Merck’s Cancer Vaccine Cuts Risk of Recurrence or Death 44% in Late-Stage, High-Risk Melanoma After Resection

An investigational therapeutic cancer vaccine following complete resection of late-stage, high-risk melanoma saw a 44% reduced likelihood of recurrence compared with pembrolizumab monotherapy. Adjuvant treatment with mRNA-4157 plus pembrolizumab showed promising results in the intention-to-treat population, with an HR of 0.56 (95% CI, 0.309-1.017) compared with pembrolizumab alone. Results were announced by the companies in a news release and presented at the American Association of Cancer Research.

Read the full article here.